Publication | Closed Access

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

Cluster HeadacheDocumented FailureClinical TrialsMigraine PreventionFremanezumab Versus PlaceboPharmacotherapyNeurologyPain ManagementMedicineHealth Sciences